Skip to content
DataLookout
Menu

NCT07924332

Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

StatusNot Yet Recruiting
PhasePhase 2
SponsorQun Zhao
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathologic Complete Response (pCR) Rate
Timeframe: After D2 radical surgery (within 8 weeks after neoadjuvant completion)

Secondary (5)

R0 Resection Rate
Event-Free Survival(EFS)
Disease-Free Survival(DFS)
Overall Survival(OS)
Safety and Tolerability

Arms and interventions

Retlirafusp Alfa Plus SOXExperimental

Retlirafusp alfa plus SOX for 3 preoperative 21-day cycles, followed by D2 radical surgery, then retlirafusp alfa plus SOX for 5 postoperative cycles, followed by retlirafusp alfa alone for 9 cycles. Retlirafusp alfa may be given for a maximum of 17 cycles in total.

Adebrelimab Plus SOXExperimental

Adebrelimab plus SOX for 3 preoperative 21-day cycles, followed by D2 radical surgery, then adebrelimab plus SOX for 5 postoperative cycles, followed by adebrelimab alone for 9 cycles. Adebrelimab may be given for a maximum of 17 cycles in total.

Drugs: Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus chemotherapy